Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe Grants Daiichi Sankyo Commercialization Rights for Edaravone in Brazil
Mitsubishi Tanabe Pharma said on September 17 that it has entered into a license agreement with Daiichi Sankyo for the commercialization rights for an intravenous infusion formulation of its amyotrophic lateral sclerosis (ALS) treatment edaravone in Brazil. Mitsubishi Tanabe also…
To read the full story
Related Article
- Radicava’s Brazil Launch Set for February 29: Mitsubishi Tanabe
February 28, 2024
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
- Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…